- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
newchinabok 发表于 2019-1-22 14:33
安全性无疑,对hbver有没有效,不试哪个知道
"安全性无疑" - 这只是您自己的观点,没有医学证据支持.
http://europepmc.org/backend/ptp ... 39&blobtype=pdf
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody
in Cancer
Drug-related grade 3 or 4 toxic effects occurred in 14% of patients who received anti–PD-1
antibody, suggesting that therapy can be delivered in an outpatient setting with minimal
supportive care. Among adverse events of special interest, pneumonitis was observed, with
findings ranging from isolated radiographic abnormalities to progressive, diffuse infiltrates
associated with clinical symptoms in a small number of patients. Although three deaths
occurred, mild-to-moderate pneumonitis was managed successfully with either observation
or glucocorticoids.
抗PD-1抗体的安全性,活性和免疫相关性在癌症
接受抗PD-1治疗的患者中有14%发生药物相关的3级或4级毒性反应
抗体,表明治疗可以在门诊病人的环境中进行,而且最少
支持性护理。 在特别感兴趣的不良事件中,观察到肺炎
研究结果从孤立的放射学异常到进行性,弥漫性浸润
与少数患者的临床症状相关。 虽然三人死亡
发生,轻度至中度肺炎成功治疗,观察
或糖皮质激素。
3例死亡(296例患者中)有20-25%的客观反应. 这在HBV治疗是否可以接受? |
|